A Study of Switching to RPV Plus Other ARVs in HIV-1-infected Children (Aged 2 to <12 Years) Who Are Virologically Suppressed

NCT04012931 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

26

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV

Interventions

DRUG: Rilpivirine
DRUG: ARV Background Regimen

Sponsor

Janssen Research & Development, LLC